Q4 2024 · 13F-HR
Vestal Point Capital, LPholdings as filed
Filed 2025-02-14 · accession 0001974915-25-000002
$1.69B
Reported value
73
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G50871105 | JAZZ | Jazz Pharmaceuticals PLC | $120.1M | 7.12% | 975,000 | Common | SOLE |
| 23282W605 | CYTK | Cytokinetics Inc | $110.5M | 6.55% | 2,350,000 | Common | SOLE |
| 58933Y105 | MRK | Merck & Co Inc | $79.6M | 4.72% | 800,000 | Common | SOLE |
| 04351P101 | ASNDUSD | Ascendis Pharma A/S | $71.6M | 4.24% | 520,000 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc | $63.1M | 3.74% | 1,500,000 | Common | SOLE |
| 457669307 | INSM | Insmed Inc | $62.1M | 3.68% | 900,000 | Common | SOLE |
| 09061G101 | BMRN | BioMarin Pharmaceutical Inc | $56.5M | 3.35% | 860,000 | Common | SOLE |
| N90064101 | QURE | uniQure NV | $53.4M | 3.17% | 3,025,000 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $47.6M | 2.82% | 1,060,000 | Common | SOLE |
| 670703107 | NUVL | Nuvalent Inc | $47.0M | 2.78% | 600,000 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc | $46.8M | 2.77% | 1,725,000 | Common | SOLE |
| 92337R101 | VERA | Vera Therapeutics Inc | $45.5M | 2.70% | 1,075,000 | Common | SOLE |
| N44445109 | IMTX | Immatics NV | $44.6M | 2.65% | 6,275,000 | Common | SOLE |
| 483497103 | KALV | KalVista Pharmaceuticals Inc | $40.4M | 2.40% | 4,770,000 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $38.9M | 2.31% | 11,000,000 | Common | SOLE |
| 04635X102 | CATBUSD | Astria Therapeutics Inc | $37.4M | 2.22% | 4,180,000 | Common | SOLE |
| 03940C100 | ACLXGBX | Arcellx Inc | $36.4M | 2.16% | 475,000 | Common | SOLE |
| 80105N105 | SNY | Sanofi SA | $36.2M | 2.14% | 750,000 | Common | SOLE |
| 37733W204 | GSK | GSK PLC | $33.8M | 2.01% | 1,000,000 | Common | SOLE |
| 805111101 | SVRA | Savara Inc | $33.1M | 1.96% | 10,775,000 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $31.8M | 1.88% | 810,000 | Common | SOLE |
| 03152W109 | AM6 | Amicus Therapeutics Inc | $31.6M | 1.87% | 3,350,000 | Common | SOLE |
| 046353108 | AZNN | AstraZeneca PLC | $31.1M | 1.85% | 475,000 | Common | SOLE |
| 803607100 | SRPT | Sarepta Therapeutics Inc | $30.4M | 1.80% | 250,000 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals Inc | $29.3M | 1.74% | 95,000 | Common | SOLE |
| 379577208 | GMED | Globus Medical Inc | $26.9M | 1.59% | 325,000 | Common | SOLE |
| 252828108 | DNTH | Dianthus Therapeutics Inc | $23.4M | 1.39% | 1,075,000 | Common | SOLE |
| B6S7WD106 | NYXH | Nyxoah SA | $23.4M | 1.39% | 2,924,216 | Common | SOLE |
| 925050106 | VRNA | Verona Pharma PLC | $23.0M | 1.36% | 495,000 | Common | SOLE |
| 462222100 | IONS | Ionis Pharmaceuticals Inc | $20.8M | 1.23% | 595,000 | Common | SOLE |
| 53635D202 | LQDA | Liquidia Corp | $20.7M | 1.23% | 1,760,000 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals Inc | $18.2M | 1.08% | 1,440,000 | Common | SOLE |
| M96088105 | URGN | UroGen Pharma Ltd | $17.4M | 1.03% | 1,630,000 | Common | SOLE |
| 52490G102 | LEGN | Legend Biotech Corp | $15.5M | 0.92% | 475,000 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd | $14.8M | 0.88% | 1,250,000 | Common | SOLE |
| 75886F107 | REGN | Regeneron Pharmaceuticals Inc | $14.2M | 0.84% | 20,000 | Common | SOLE |
| G31249108 | ESTA | Establishment Labs Holdings In | $13.8M | 0.82% | 300,000 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences Inc | $13.8M | 0.82% | 990,000 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc | $12.4M | 0.73% | 710,000 | Common | SOLE |
| 09203E105 | BDTX | Black Diamond Therapeutics Inc | $12.0M | 0.71% | 5,600,000 | Common | SOLE |
| 83422E204 | SLDB | Solid Biosciences Inc | $11.4M | 0.68% | 2,850,000 | Common | SOLE |
| 00846U101 | A | Agilent Technologies Inc | $10.1M | 0.60% | 75,000 | Common | SOLE |
| 03828A101 | APLT | Applied Therapeutics Inc | $9.8M | 0.58% | 11,500,000 | Common | SOLE |
| G97822103 | PRGO | Perrigo Co PLC | $9.6M | 0.57% | 375,000 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics Inc | $9.1M | 0.54% | 485,000 | Common | SOLE |
| 52886X107 | LXEO | Lexeo Therapeutics Inc | $7.9M | 0.47% | 1,200,000 | Common | SOLE |
| 98887Q104 | ZLAB | Zai Lab Ltd | $7.9M | 0.47% | 300,000 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics Inc | $7.7M | 0.46% | 305,000 | Common | SOLE |
| 92915B106 | VYGR | Voyager Therapeutics Inc | $7.0M | 0.41% | 1,230,000 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics Inc | $6.9M | 0.41% | 900,000 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics Inc | $6.1M | 0.36% | 525,000 | Common | SOLE |
| 68277Q105 | OKUR | OnKure Therapeutics Inc | $5.5M | 0.32% | 635,000 | Common | SOLE |
| 36315X101 | LKFT | Galapagos NV | $5.0M | 0.29% | 180,000 | Common | SOLE |
| 16934W106 | CMRXEUR | Chimerix Inc | $4.9M | 0.29% | 1,400,000 | Common | SOLE |
| 869367102 | — | Sutro Biopharma Inc | $4.7M | 0.28% | 2,570,000 | Common | SOLE |
| 92332V107 | VTYXUSD | Ventyx Biosciences Inc | $4.4M | 0.26% | 2,000,000 | Common | SOLE |
| 31189P102 | FATE | Fate Therapeutics Inc | $4.1M | 0.24% | 2,465,000 | Common | SOLE |
| 02157Q109 | ANRO | Alto Neuroscience Inc | $3.9M | 0.23% | 915,000 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics Inc | $3.6M | 0.22% | 645,000 | Common | SOLE |
| 702712100 | — | Passage Bio Inc | $3.5M | 0.21% | 6,100,000 | Common | SOLE |
| 019770106 | ALLO | Allogene Therapeutics Inc | $3.2M | 0.19% | 1,500,000 | Common | SOLE |
| 89377M109 | TMDX | TransMedics Group Inc | $3.1M | 0.18% | 50,000 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics Inc | $2.9M | 0.17% | 425,000 | Common | SOLE |
| 98985Y108 | ZYME | Zymeworks Inc | $2.7M | 0.16% | 185,000 | Common | SOLE |
| 29286M105 | — | Engene Holdings Inc | $2.5M | 0.15% | 370,000 | Common | SOLE |
| 071734107 | BHC | Bausch Health Cos Inc | $2.0M | 0.12% | 250,000 | Common | SOLE |
| 64135M105 | NGNE | Neurogene Inc | $1.8M | 0.11% | 80,000 | Common | SOLE |
| 00449L102 | 698 | Achilles Therapeutics PLC | $1.7M | 0.10% | 1,500,000 | Common | SOLE |
| 046513206 | ATRA | Atara Biotherapeutics Inc | $1.7M | 0.10% | 125,000 | Common | SOLE |
| 45258J102 | IMVT | Immunovant Inc | $1.1M | 0.07% | 45,000 | Common | SOLE |
| 556099109 | MGNX | MacroGenics Inc | $910,000 | 0.05% | 280,000 | Common | SOLE |
| 68232V884 | TRAW | Traws Pharma Inc | $666,000 | 0.04% | 75,000 | Common | SOLE |
| 88032L605 | TENX | Tenax Therapeutics Inc | $341,620 | 0.02% | 55,189 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.